Medicines Australia Chair Retires
This article was originally published in Scrip
Medicines Australia's chair, Dr. Martin Cross, will be retiring from the board after nearly 30 years in the pharmaceutical industry – effective Oct. 20, 2015. Cross was appointed Medicines Australia's chair in 2013, joining the industry association from Alphapharm, where he was managing director. Under his leadership came the development of COMPARE, a new regular industry report; the re-launch of the Access to Medicines working group and consultation; as well as authorization and implementation of the 18th edition of the Code of Conduct which encompasses a sector-leading transparency. As his exit from Medicine's Australia approaches, Cross has expressed his biggest concerns for the industry. He highlighted the effect of budget related cuts on the sector and his disappointment of failing to come to a strategic agreement with the government before his retirement. Medicines Australia's new board and replacement chair will be announced on 20th October at the association's annual general meeting.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.